Back to Results
First PageMeta Content
Medicine / Exenatide / Incretin / Glucagon-like peptide-1 analog / Anti-diabetic medication / Glucagon-like peptide-1 / European Medicines Agency / Sulfonylurea / Insulin resistance / Anti-diabetic drugs / Endocrine system / Gastroenterology


Assessment report for
Add to Reading List

Document Date: 2013-07-21 06:16:23


Open Document

File Size: 1,06 MB

Share Result on Facebook

City

London / /

Company

AMP / Eli Lilly Nederland B.V. / /

Country

United States / United Kingdom / /

/

Facility

Canary Wharf / /

IndustryTerm

pharmaceutical and biological aspects / pharmaceutical development / drug product / medicinal product / downstream processing / manufacturing sites / sterile product / aseptic manufacturing process / rubber / chemical / chemical structure / medicinal products / manufacturing processes / closed manufacturing system / manufacturing process / /

MedicalCondition

insulin resistance / chronic widespread disease / sterility / diabetes / transmittable spongiform encephalitis / diabetes mellitus / type 2 diabetes mellitus / /

MedicalTreatment

oral therapies / /

Organization

European Medicines Agency / European Commission / European Union / E-mail info@ema.europa.eu Website www.ema.europa.eu An / CHMP / /

Person

Ion Chromatography / Pieter de Graeff / /

/

Product

Byetta / sodium chloride / glucagon / glycine / /

Technology

Pharmacokinetics / antibodies / Gas Chromatography / Pharmacodynamics / recombinant DNA technology / /

URL

www.ema.europa.eu / /

SocialTag